Piramal Pharma543635Stock price alert
Clarification: Ontario's $1.7 Million LSSUF Funding for Aurora Facility Not Material
Company clarifies on a news report about its Aurora facility in Ontario.
- Funding Amount
- $1.7 Million funding support from the Government of Ontario under the Life Sciences Scale-Up Fund
- Use of Funding
- infrastructure upgrades, site modernization, operational efficiency and sustainability
- Materiality Statement
- not expected to have a material impact on operations, financial position or performance
- Facility
- Aurora facility in Ontario
Ontario funding in the news
- A news item dated September 30, 2026 on thehindubusinessline.com was titled "Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility."
- The company clarified that this pertains to funding support received by its Aurora facility from the Government of Ontario under the Life Sciences Scale-Up Fund (LSSUF) program.
- The program aims to support innovative Ontario-based life sciences companies in scaling their operations and responding to procurement opportunities.
What the funding is meant for
- Infrastructure upgrades
- Site modernization
- Operational efficiency
- Sustainability initiatives
- Other enhancement projects at the Aurora facility
Expected benefits as stated
- Employment generation and retention
- Support for innovation and commercialization initiatives
- Strengthening the broader life sciences and biomanufacturing ecosystem in Ontario
How the company has sized it
- The company said the funding support does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- It said the funding is not expected to have a material impact on its operations, financial position, or performance.
Share price and volume movement
- The company said any movement in the price and/or volume of its shares appears to be driven by market dynamics.
- It said it is not aware of any specific reason or information that may have resulted in such movement.
What a retail investor can take away
- This is a clarification sent to the exchange about a news report that had already appeared, not a fresh announcement of a new order, contract or fundraise.
- The figure referred to in the news item, and addressed in the clarification, is $1.7 Million of funding support.
- The company's own stated position is that this is not expected to be material to its operations, financial position, or performance.
Also from Piramal Pharma
Bayer sales & distribution arrangement to expire on 31st December, 2026; will not be renewed
1 Oct 2026
Viral Gandhi appointed Chief Technology Officer from 1 October 2026
30 Sep 2026
Leadership change at Piramal Critical Care: Jeffrey Hampton to retire, Brian Guy appointed President & COO
30 Sep 2026
More numbers
- Ontario funding support referred to in the news item$1.7 Million
Source: BSE · 1 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.